About Cutaneous Lymphoma

Allos Therapeutics Announces FDA Advisory Committee Recommends Accelerated Approval of FOLOTYN (pralatrexate) for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

Wed, 09/02/2009


Click here to read more on this news.

English French German Italian Portuguese Russian Spanish

This is an automatic translation service and therefore the
Cutaneous Lymphoma Foundation is not responsible
for any potential translation inaccuracies.